https://tcrshows.com/ 2026-08-15 1.0 https://tcrshows.com/database 2026-08-08 0.8 https://tcrshows.com/learning 2026-08-13 0.8 https://tcrshows.com/services 2026-06-16 0.8 https://tcrshows.com/knowledge 2026-08-08 0.7 https://tcrshows.com/tools 2026-08-12 0.6 https://tcrshows.com/structure 2026-08-08 0.6 https://tcrshows.com/hla 2026-08-08 0.6 https://tcrshows.com/offtarget 2026-08-08 0.6 https://tcrshows.com/repertoire 2026-08-08 0.6 https://tcrshows.com/mrna 2026-08-08 0.6 https://tcrshows.com/mrna-tcr 2026-08-08 0.6 https://tcrshows.com/mrna-vaccine 2026-08-08 0.6 https://tcrshows.com/article/two-tcrdesign-de-novo-routes 2026-08-13 0.7 https://tcrshows.com/article/wt1-heteroclitic-yl9-tcr-kinetic-penalty 2026-08-10 0.7 https://tcrshows.com/article/slide-gotags-spatial-neoantigen-tcr 2026-07-27 0.7 https://tcrshows.com/article/tcr-phla-prediction-sequence-vs-structure 2026-07-22 0.7 https://tcrshows.com/article/immunoscape-msln-hla-a1101-tcr-offtarget 2026-07-16 0.7 https://tcrshows.com/article/protocol-rna-preamp-single-cell-tcr 2026-07-09 0.7 https://tcrshows.com/article/gpc3-vaccine-derived-tcr-t-hepatoblastoma 2026-07-03 0.7 https://tcrshows.com/article/tcr-t-enhancement-strategies-solid-tumor 2026-06-25 0.7 https://tcrshows.com/article/foxm1-tcr-t-nsclc 2026-06-18 0.7 https://tcrshows.com/article/neoantigen-tcr-t-solid-tumor-review 2026-06-09 0.7 https://tcrshows.com/article/asco-2026-tcr-t-tce-trials 2026-06-04 0.7 https://tcrshows.com/article/ai-designed-tcr-physics-simulation 2026-05-26 0.7 https://tcrshows.com/article/peptide-recognition-profiling-tcr-specificity 2026-05-19 0.7 https://tcrshows.com/article/de-novo-disulfide-tcr-pairing 2026-05-12 0.7 https://tcrshows.com/article/mptcrai-structure-energetics-tcr-design 2026-04-22 0.7 https://tcrshows.com/article/cd28-motif-cd3zeta-tcr-t 2026-04-15 0.7 https://tcrshows.com/article/tcr-t-therapy-progress-challenges 2026-04-07 0.7 https://tcrshows.com/article/eso-t01-in-vivo-car-t-mm 2026-03-30 0.7 https://tcrshows.com/article/kras-g12v-tcr-t-pancreatic-phase12 2026-03-20 0.7 https://tcrshows.com/article/ifna-anti-pdl1-secreting-tcr-t 2026-03-13 0.7 https://tcrshows.com/article/phla-complex-disease-driver 2026-01-23 0.7 https://tcrshows.com/article/phla-targeted-precision-immunotherapy 2026-01-16 0.7 https://tcrshows.com/article/adapt-ai-designed-tcr-tcrm-pmhc 2026-01-08 0.7 https://tcrshows.com/article/tcr-t-preclinical-clinical-challenges 2025-12-30 0.7 https://tcrshows.com/article/lymphodepletion-boosts-neoantigen-presentation 2025-12-24 0.7 https://tcrshows.com/article/tcr-cd3-resting-vs-ligand-bound-structure 2025-12-18 0.7 https://tcrshows.com/article/kras-g12d-peptide-length-immunogenicity 2025-12-12 0.7 https://tcrshows.com/article/ald-lipid-free-thermostable-mrna-vaccine 2025-12-04 0.7 https://tcrshows.com/article/pmgen-pmhc-modeling-neoantigen-generation 2025-11-27 0.7 https://tcrshows.com/article/cancer-cell-therapy-global-trial-trends 2025-11-14 0.7 https://tcrshows.com/article/neoantigen-identification-prediction-validation 2025-11-05 0.7 https://tcrshows.com/article/lete-cel-ny-eso-1-nsclc 2025-10-28 0.7 https://tcrshows.com/article/mrna-custom-apc-ny-eso-1-ctl 2025-10-21 0.7 https://tcrshows.com/article/tcr-affinity-avidity-functional-avidity 2025-10-14 0.7 https://tcrshows.com/article/dna-directed-bispecific-lnp-t-cell-delivery 2025-09-24 0.7 https://tcrshows.com/article/protocol-optofluidic-tumor-reactive-t-cells-mm-aml 2025-09-19 0.7 https://tcrshows.com/article/wt1-tcr-like-single-domain-antibody 2025-09-11 0.7 https://tcrshows.com/article/protocol-mrna-electroporation-viral-tcr-t 2025-09-05 0.7 https://tcrshows.com/article/t-cell-engager-expanding-horizons 2025-08-28 0.7 https://tcrshows.com/article/dextran-doped-pmhc-tcr-dextramer-protocol 2025-08-22 0.7 https://tcrshows.com/article/tcr-repertoire-guided-therapeutic-tcr-selection 2025-08-15 0.7 https://tcrshows.com/article/integrated-tcr-epitope-hla-screening-system 2025-08-07 0.7 https://tcrshows.com/article/hbv-tcr-t-post-liver-transplant-hcc 2025-07-30 0.7 https://tcrshows.com/article/cqmu-kras-g12v-d-tcr-engineering 2025-07-23 0.7 https://tcrshows.com/article/kras-g12v-tcr-051-ind-study 2025-07-17 0.7 https://tcrshows.com/article/lag3-tcr-proximity-bispecific-autoimmunity 2025-07-10 0.7 https://tcrshows.com/article/ifng-high-ctl-enhanced-cytotoxicity 2025-07-02 0.7 https://tcrshows.com/article/tcr-structure-prediction-tools-benchmark 2025-06-25 0.7 https://tcrshows.com/article/removing-classic-disulfide-reduces-tcr-mispairing 2025-06-18 0.7 https://tcrshows.com/article/tope-seq-autoantigen-crossreactivity-screening 2025-06-13 0.7 https://tcrshows.com/article/t-cell-immunotherapy-advances-part2 2025-06-04 0.7 https://tcrshows.com/article/t-cell-immunotherapy-advances-part1 2025-06-04 0.7 https://tcrshows.com/article/protocol-til-tcr-t-cytotoxicity-assay 2025-05-14 0.7 https://tcrshows.com/article/thlanet-tcr-phla-binding-prediction 2025-04-29 0.7 https://tcrshows.com/article/ddpcr-vector-copy-number-assay 2025-04-23 0.7 https://tcrshows.com/article/ima203-prame-tcr-t-phase1 2025-04-17 0.7 https://tcrshows.com/article/protocol-in-vitro-antigen-specific-ctl 2025-04-10 0.7 https://tcrshows.com/article/mal-id-bcr-tcr-disease-diagnosis 2025-04-03 0.7 https://tcrshows.com/article/tcr-t-solid-tumor-challenges-solutions 2025-03-27 0.7 https://tcrshows.com/article/hla-a02-subtypes-tecelra-eligibility 2025-03-19 0.7 https://tcrshows.com/article/t-cell-avidity-and-measurement 2025-03-10 0.7 https://tcrshows.com/article/t-cell-immunity-fundamentals 2025-03-06 0.7 https://tcrshows.com/article/shm-tcr-avidity-maturation 2025-02-26 0.7 https://tcrshows.com/article/tfold-tcr-and-tcrstructdb 2025-02-18 0.7 https://tcrshows.com/article/tcr-t-new-era-clinical-landscape 2025-02-11 0.7 https://tcrshows.com/article/biopsy-based-high-throughput-tcr-discovery 2025-01-22 0.7 https://tcrshows.com/article/chimeric-syngeneic-model-tcr-affinity 2025-01-13 0.7 https://tcrshows.com/article/human-tcr-trav-traj-trbv-trbj-sequences 2025-01-08 0.7 https://tcrshows.com/article/vlp-open-hla-nanoparticle-screening 2024-12-26 0.7 https://tcrshows.com/article/tcr-t-hematologic-malignancies-trials 2024-12-19 0.7 https://tcrshows.com/article/hla-a2-gpc3-mouse-tcr-hcc-vs-cart 2024-12-11 0.7 https://tcrshows.com/article/radium-1-mrna-tcr-msi-h-crc 2024-12-02 0.7 https://tcrshows.com/article/trait-tcr-antigen-interaction-database 2024-11-27 0.7 https://tcrshows.com/article/four-kras-g12v-tcr-comparison 2024-11-05 0.7 https://tcrshows.com/article/tcr-t-aml-challenges-strategies 2024-10-30 0.7 https://tcrshows.com/article/kras-methylation-ptm-immune-escape 2024-10-23 0.7 https://tcrshows.com/article/whole-blood-assay-tcr-t-in-vivo-function 2024-10-15 0.7 https://tcrshows.com/article/tcr-t-preclinical-evaluation-regulatory 2024-10-10 0.7 https://tcrshows.com/article/antigen-agnostic-tcr-screening-kras-q61h 2024-09-25 0.7 https://tcrshows.com/article/personalized-mrna-vaccine-pd1-escc 2024-09-20 0.7 https://tcrshows.com/article/protocol-viral-mrna-tcr-primary-t-cells 2024-09-11 0.7 https://tcrshows.com/article/b7-lfa3-icam1-costimulation-signatures 2024-09-05 0.7 https://tcrshows.com/article/weak-tcr-crossreactivity-autoimmunity 2024-08-29 0.7 https://tcrshows.com/article/gratcr-epitope-specific-tcr-generation 2024-08-14 0.7 https://tcrshows.com/article/tecelra-afami-cel-fda-approval 2024-08-02 0.7 https://tcrshows.com/article/comprehensive-solution-tcr-therapy-solid-tumor 2024-07-31 0.7 https://tcrshows.com/article/rosenberg-personalized-neoantigen-tcr-crc 2024-07-19 0.7 https://tcrshows.com/article/pik3ca-h1047l-tcr-t-development 2024-07-16 0.7 https://tcrshows.com/article/antigen-liposome-universal-tcr-t 2024-07-11 0.7 https://tcrshows.com/article/tumor-organoid-coculture-tcr-discovery 2024-07-05 0.7 https://tcrshows.com/article/rujin-kras-g12v-mrna-pd1 2024-06-29 0.7 https://tcrshows.com/article/mage-a4-hla-a02-patient-eligibility 2024-06-18 0.7 https://tcrshows.com/article/protocol-neoantigen-t-cells-healthy-donor 2024-06-12 0.7 https://tcrshows.com/article/dual-antigen-single-epitope-tcr-t 2024-05-31 0.7 https://tcrshows.com/article/protocol-scrnaseq-tcr-functional-screening 2024-05-15 0.7 https://tcrshows.com/article/il21r-engineered-tcr-t-hcc 2024-05-08 0.7 https://tcrshows.com/article/car-tcr-t-dual-target-aml 2024-04-30 0.7 https://tcrshows.com/article/rootpath-massively-parallel-tcr-discovery 2024-04-25 0.7 https://tcrshows.com/article/cd39-knockout-tcr-t-antitumor 2024-04-23 0.7 https://tcrshows.com/article/optimizing-act-part3-combination-derivatives 2024-04-15 0.7 https://tcrshows.com/article/optimizing-act-part2-applications-limits 2024-04-15 0.7 https://tcrshows.com/article/optimizing-act-part1-antigen-and-tcr 2024-04-15 0.7 https://tcrshows.com/article/cfse-based-antigen-specific-tcr-isolation 2024-04-08 0.7 https://tcrshows.com/article/tcr-t-cancer-therapy-progress-review 2024-04-03 0.7 https://tcrshows.com/article/allo-hsct-car-t-tcr-t-strategies 2024-04-01 0.7 https://tcrshows.com/article/tcr-antigen-screening-technologies 2024-03-27 0.7 https://tcrshows.com/article/scseq-organoid-pdac-tumor-reactive-tcr 2024-03-20 0.7 https://tcrshows.com/article/neotcr-neoantigen-specific-tcr-database 2024-03-14 0.7 https://tcrshows.com/article/hla-a3-kras-g12v-tcr-structure 2024-03-07 0.7 https://tcrshows.com/article/cd3zeta-boosts-tcr-expression 2024-02-26 0.7 https://tcrshows.com/article/t2-cells-antigen-presentation-uses 2024-02-22 0.7 https://tcrshows.com/article/esr1-neoepitope-processing-discrepancy 2024-01-31 0.7 https://tcrshows.com/article/wt1-tcr-from-allo-hla-repertoire 2024-01-25 0.7 https://tcrshows.com/article/dtc-relative-scarcity-immune-escape 2024-01-11 0.7 https://tcrshows.com/article/framework-residues-boost-tcr-expression 2023-12-25 0.7 https://tcrshows.com/article/tcr-based-immunotherapy-progress 2023-12-19 0.7 https://tcrshows.com/article/tebentafusp-3-year-overall-survival 2023-12-15 0.7 https://tcrshows.com/article/haul-tcr-t-membrane-fusion-nanoparticle 2023-12-11 0.7 https://tcrshows.com/article/neoantigen-tcr-t-progress-challenges 2023-12-06 0.7 https://tcrshows.com/article/cancer-immunity-cycle 2023-12-01 0.7 https://tcrshows.com/article/lnp-codelivery-mrna-sirna-pd1-knockdown 2023-11-22 0.7 https://tcrshows.com/article/tcr-t-optimization-strategies 2023-11-21 0.7 https://tcrshows.com/article/one-tcr-multiple-tumor-antigens 2023-11-17 0.7 https://tcrshows.com/article/tcr-drug-candidate-discovery-safety 2023-11-10 0.7 https://tcrshows.com/article/seven-tcr-based-molecular-formats 2023-11-06 0.7 https://tcrshows.com/article/structure-guided-tcrm-antibody-isolation 2023-10-31 0.7 https://tcrshows.com/article/afami-cel-adp-a2m4cd8-clinical-data 2023-10-26 0.7 https://tcrshows.com/article/shared-neoepitope-hla-discovery-platform 2023-10-25 0.7 https://tcrshows.com/article/neoantigen-vaccine-post-delivery-barriers 2023-10-16 0.7 https://tcrshows.com/article/designing-effective-neoantigen-vaccines 2023-10-12 0.7 https://tcrshows.com/article/tcr-therapy-generations-and-pipeline 2023-10-09 0.7 https://tcrshows.com/article/lamc2-tcr-t-pdac-mass-spec-epitope 2023-09-27 0.7 https://tcrshows.com/article/neoantigen-tcr-t-full-pipeline-part1 2023-09-18 0.7 https://tcrshows.com/article/neoantigen-tcr-t-full-pipeline-part2 2023-09-18 0.7 https://tcrshows.com/article/amp-lymph-node-targeted-vaccine-tcr-t 2023-09-13 0.7 https://tcrshows.com/article/ny-eso-1-cancer-vaccines-solid-tumors 2023-09-07 0.7 https://tcrshows.com/article/taest16001-trial-design-and-methods 2023-09-04 0.7 https://tcrshows.com/article/act-gene-transduction-technologies 2023-08-30 0.7 https://tcrshows.com/article/tcr-t-challenges-and-new-technologies 2023-08-28 0.7 https://tcrshows.com/article/taest16001-phase1-soft-tissue-sarcoma 2023-08-22 0.7 https://tcrshows.com/article/deepair-sequence-structure-tcr-analysis 2023-08-15 0.7 https://tcrshows.com/article/tcrmodel2-deep-learning-tcr-pmhc 2023-08-09 0.7 https://tcrshows.com/article/tcr-nk-cells-adoptive-immunotherapy 2023-07-31 0.7 https://tcrshows.com/article/humanized-mouse-models-immuno-oncology 2023-07-19 0.7 https://tcrshows.com/article/engineered-tcr-t-production-and-application 2023-07-11 0.7 https://tcrshows.com/article/yamtad-yeast-agglutination-tcr-screening 2023-06-28 0.7 https://tcrshows.com/article/phla-immunotherapy-platform-immuno-stat 2023-06-25 0.7 https://tcrshows.com/article/mrna-encoded-car-tcr-engineered-t-cells 2023-06-16 0.7 https://tcrshows.com/article/structural-avidity-neoantigen-cd8-tumor-residency 2023-06-12 0.7 https://tcrshows.com/article/regeneron-tcr-cd3-pmhc-cryoem 2023-06-06 0.7 https://tcrshows.com/article/mrna-vaccine-lnp-and-administration-routes 2023-06-05 0.7 https://tcrshows.com/article/jurkat-reporter-microfluidics-tcr-screening 2023-05-29 0.7 https://tcrshows.com/article/t-cell-antigen-discovery-methods 2023-05-19 0.7 https://tcrshows.com/article/tcr-mimic-antibodies-immunotherapy 2023-05-15 0.7 https://tcrshows.com/article/suplexa-autologous-adoptive-cell-therapy 2023-05-05 0.7 https://tcrshows.com/article/mrna-4650-neoantigen-vaccine-gi-cancers 2023-04-27 0.7 https://tcrshows.com/article/tcr-chain-synthesis-and-rearrangement 2023-04-17 0.7 https://tcrshows.com/article/tcr-structure-and-biology 2023-04-03 0.7 https://tcrshows.com/article/lmp2-mrna-vaccine-nasopharyngeal-carcinoma 2023-03-30 0.7 https://tcrshows.com/article/neoantigen-hla-capture-library-pd1-blockade 2023-03-23 0.7 https://tcrshows.com/article/mrna-nanocarrier-in-vivo-car-tcr-programming 2023-03-15 0.7 https://tcrshows.com/article/neoantigen-clinical-challenges-and-outlook 2023-03-07 0.7 https://tcrshows.com/article/neoantigen-based-therapeutic-strategies 2023-03-03 0.7 https://tcrshows.com/article/neoantigen-series-identification-and-prediction 2023-02-22 0.7 https://tcrshows.com/article/tcr-t-solid-tumors-technologies-and-prospects 2023-02-19 0.7 https://tcrshows.com/article/neoantigen-sources-and-origins 2023-02-16 0.7 https://tcrshows.com/article/immunomodulation-strategies-for-cell-therapy 2023-02-09 0.7 https://tcrshows.com/article/tumor-mrna-vaccine-progress-and-challenges 2023-02-01 0.7 https://tcrshows.com/article/personalized-neotcr-t-cell-therapy 2023-01-19 0.7 https://tcrshows.com/article/afami-cel-phase1-mage-a4-solid-tumors 2023-01-11 0.7 https://tcrshows.com/article/cell-and-gene-therapy-in-china 2022-12-31 0.7 https://tcrshows.com/article/china-gct-dual-track-regulation 2022-12-29 0.7 https://tcrshows.com/service/tcr-molecule-tcrt-construction 2026-06-16 0.7 https://tcrshows.com/service/apc-construction-tcr-screening 2026-06-16 0.7 https://tcrshows.com/service/high-throughput-natural-tcr-discovery 2026-06-16 0.7 https://tcrshows.com/service/antigen-t-cell-reactivity-assay 2026-06-16 0.7 https://tcrshows.com/service/engineered-apc-target-cell-construction 2026-06-16 0.7 https://tcrshows.com/service/tcrt-in-vivo-validation 2026-06-16 0.7 https://tcrshows.com/service/tumor-therapeutic-vaccine 2026-06-16 0.7 https://tcrshows.com/service/mrna-lnp-encapsulation-qc 2026-06-16 0.7 https://tcrshows.com/service/mrna-vaccine-functional-antitumor 2026-06-16 0.7 https://tcrshows.com/service/phla-target-identification-validation 2026-06-16 0.7 https://tcrshows.com/service/mhc-tetramer 2026-06-16 0.7 https://tcrshows.com/service/hla-typing 2026-06-16 0.7 https://tcrshows.com/service/soluble-tcr-protein-expression 2026-06-16 0.7 https://tcrshows.com/service/cell-line-overexpression-knockdown 2026-06-16 0.7